

# Mohamad E Allaf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8776333/publications.pdf>

Version: 2024-02-01

126  
papers

4,260  
citations

147566

31  
h-index

123241

61  
g-index

127  
all docs

127  
docs citations

127  
times ranked

6091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 113-117.	2.6	30
2	Self-reported quality of life as a predictor of mortality in renal cell carcinoma. <i>Cancer</i> , 2022, 128, 479-486.	2.0	3
3	Patient and in-hospital predictors of post-discharge opioid utilization: Individualizing prescribing after radical prostatectomy based on the ORIOLES initiative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 104.e9-104.e15.	0.8	4
4	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	1.2	6
5	Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 5015-5015.	0.8	3
6	A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid use. <i>World Journal of Urology</i> , 2021, 39, 1845-1851.	1.2	3
7	Cost-effectiveness Analysis of 99mTc-sestamibi SPECT/CT to Guide Management of Small Renal Masses. <i>European Urology Focus</i> , 2021, 7, 827-834.	1.6	16
8	Evidence-based analysis of online consumer information about prostate artery embolization for benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 106-113.	2.0	7
9	Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. <i>Journal of Robotic Surgery</i> , 2021, 15, 309-313.	1.0	7
10	Comparison of Perioperative and Pathologic Outcomes Between Single-port and Standard Robot-assisted Radical Prostatectomy: An Analysis of a High-volume Center and the Pooled World Experience. <i>Urology</i> , 2021, 147, 223-229.	0.5	20
11	Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial. <i>BJU International</i> , 2021, 127, 190-197.	1.3	6
12	Evidence-based quality and accuracy of YouTube videos about nephrolithiasis. <i>BJU International</i> , 2021, 127, 247-253.	1.3	23
13	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [ <sup>111</sup> In]In- <sup>67</sup> YIMSR <sup>01</sup> for phase I regulatory approval. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 243-250.	0.5	2
14	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. <i>Journal of Urology</i> , 2021, 205, 1069-1074.	0.2	21
15	PROSPER: Phase III Randomized Study Comparing Perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4596-TPS4596.	0.8	5
16	Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial. <i>Journal of Urology</i> , 2021, 205, 1681-1688.	0.2	3
17	Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 439.e1-439.e8.	0.8	1
18	Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>Eur Urol</i> 2021;79:334-348. <i>European Urology</i> , 2021, 80, e33-e34.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. <i>Urology</i> , 2021, 154, 201-207.	0.5	5
20	Freehand Transperineal Prostate Biopsy with Three-Dimensional Ultrasound Organ-Based Tracking. <i>Journal of Endourology</i> , 2021, 35, S-7-S-16.	1.1	3
21	Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e17-735.e23.	0.8	14
22	Prospective Evaluation of PSMA-Targeted <sup>18</sup> F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 58-61.	2.8	61
23	Stage-specific conditional survival in renal cell carcinoma after nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 6.e1-6.e7.	0.8	15
24	Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer. <i>Urology</i> , 2020, 135, 76-81.	0.5	25
25	Adjuvant Therapy for Urothelial and Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 6, 3-6.	1.6	6
26	Effect of a prospective opioid reduction intervention on opioid prescribing and use after radical prostatectomy: results of the Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) Initiative. <i>BJU International</i> , 2020, 125, 426-432.	1.3	26
27	Transperineal prostate biopsy with cognitive magnetic resonance imaging/biplanar ultrasound fusion: description of technique and early results. <i>World Journal of Urology</i> , 2020, 38, 1943-1949.	1.2	39
28	Cost-effectiveness Analysis of Non-risk-adapted Active Surveillance for Postorchiectomy Management of Clinical Stage I Seminoma. <i>European Urology Focus</i> , 2020, 7, 1409-1417.	1.6	4
29	Detection of a Meckel's diverticulum on PSMA PET/CT: A case report. <i>Urology Case Reports</i> , 2020, 33, 101306.	0.1	0
30	4540 THE IMPACT OF SURGEON AND HOSPITAL VOLUME ON 30-DAY OUTCOMES AND COST FOR RENAL CANCER SURGERY. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 148-148.	0.3	0
31	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>European Urology</i> , 2020, 78, 360-368.	0.9	22
32	Incidental periprostatic schwannoma discovered during evaluation for prostatic adenocarcinoma. <i>Urology Case Reports</i> , 2020, 31, 101150.	0.1	5
33	Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. <i>Cancer</i> , 2020, 126, 1632-1639.	2.0	8
34	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5101-TPS5101.	0.8	3
35	Primary and post-chemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: a review. <i>Translational Andrology and Urology</i> , 2020, 9, 949-958.	0.6	15
36	Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. <i>BJU International</i> , 2019, 123, 42-50.	1.3	65

#	ARTICLE	IF	CITATIONS
37	Incidentally Detected <sup>18</sup> F-FDG-Avid Prostate Cancer Diagnosed Using a Novel Fusion Biopsy Platform. <i>Journal of Endourology Case Reports</i> , 2019, 5, 68-70.	0.3	1
38	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	1.1	35
39	In-office Transperineal Prostate Biopsy Using Biplanar Ultrasound Guidance: A Step-by-Step Guide. <i>Urology</i> , 2019, 133, 247.	0.5	17
40	Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 519-524.	0.8	18
41	Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2019, 33, 617-623.	1.2	40
42	Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. <i>European Urology Oncology</i> , 2019, 2, 343-348.	2.6	95
43	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [ <sup>18</sup> F]DCFPyL PET/CT. <i>Molecular Imaging and Biology</i> , 2019, 21, 567-573.	1.3	46
44	Activation and Proliferation of PD-1+ Kidney Double-Negative T Cells Is Dependent on Nonclassical MHC Proteins and IL-2. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 277-292.	3.0	27
45	A Prospective Cohort Study of Postdischarge Opioid Practices After Radical Prostatectomy: The ORIOLES Initiative. <i>European Urology</i> , 2019, 75, 215-218.	0.9	48
46	Intraoperative Nerve Monitoring in Robotic-Assisted Resection Of Presacral Ganglioneuroma: Operative Technique. <i>Operative Neurosurgery</i> , 2019, 16, 103-110.	0.4	6
47	Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: The ERECT Trial. <i>European Urology Focus</i> , 2019, 5, 698-699.	1.6	1
48	Selecting Patients with Small Renal Masses for Active Surveillance: A Domain Based Score from a Prospective Cohort Study. <i>Journal of Urology</i> , 2019, 201, 886-892.	0.2	15
49	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4597-TPS4597.	0.8	3
50	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS684-TPS684.	0.8	11
51	Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA-targeted <sup>99m</sup> Tc-MIP-1404 SPECT/CT.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16572-e16572.	0.8	0
52	Photorealistic 3-Dimensional Cinematic Rendering of Clear Cell Renal Cell Carcinoma From Volumetric Computed Tomography Data. <i>Urology</i> , 2018, 115, e3-e5.	0.5	11
53	Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. <i>Urology</i> , 2018, 115, 8-13.	0.5	65
54	<sup>99m</sup> Tc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide. <i>British Journal of Radiology</i> , 2018, 91, 20170526.	1.0	15

#	ARTICLE	IF	CITATIONS
55	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
56	Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. <i>Journal of Nuclear Medicine</i> , 2018, 59, 871-877.	2.8	115
57	Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. <i>Annals of Nuclear Medicine</i> , 2018, 32, 69-74.	1.2	28
58	Multiple growth periods predict unfavourable pathology in patients with small renal masses. <i>BJU International</i> , 2018, 121, 732-736.	1.3	14
59	Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes. <i>World Journal of Urology</i> , 2018, 36, 73-78.	1.2	15
60	Use of quantitative SPECT/CT reconstruction in 99mTc-sestamibi imaging of patients with renal masses. <i>Annals of Nuclear Medicine</i> , 2018, 32, 87-93.	1.2	17
61	Use of 99m Tc-sestamibi Single-photon Emission Computed Tomography / X-ray Computed Tomography in the Diagnosis of Hybrid Oncocytic / Chromophobe Tumor in a Pediatric Patient. <i>Urology</i> , 2018, 113, 206-208.	0.5	5
62	Margin Assessment in Renal Surgery Using a Handheld Optical Coherence Tomography Probe. <i>Urology</i> , 2018, 113, 241-245.	0.5	2
63	Prostate Specific Membrane Antigen Targeted <sup>18</sup> F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018, 199, 126-132.	0.2	86
64	Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3601-3607.	0.8	16
65	Spontaneous Regression of a Low-Grade Renal Cell Carcinoma With Oncocytic Features After Renal Mass Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1083-e1085.	0.9	6
66	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518.	0.8	18
67	Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5099-TPS5099.	0.8	13
68	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS710-TPS710.	0.8	1
69	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4597-TPS4597.	0.8	0
70	Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. <i>European Urology</i> , 2017, 71, 476-482.	0.9	85
71	PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. <i>European Urology</i> , 2017, 71, 145-146.	0.9	40
72	Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. <i>BJU International</i> , 2017, 119, 661-666.	1.3	71

#	ARTICLE	IF	CITATIONS
73	Renal Pseudoaneurysm Mimicking Local Cancer Recurrence After Partial Nephrectomy. Urology Case Reports, 2017, 11, 1-3.	0.1	2
74	The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. European Urology Focus, 2017, 3, 584-589.	1.6	17
75	Defining the Role of Intraoperative Transesophageal Echocardiography During Radical Nephrectomy With Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. Urology, 2017, 107, 161-165.	0.5	22
76	Semiquantitative Parameters in PSMA-Targeted PET Imaging with <sup>18</sup> F-DCFPyL: Variability in Normal-Organ Uptake. Journal of Nuclear Medicine, 2017, 58, 942-946.	2.8	38
77	Consumer Preferences and Online Comparison Tools Used to Select a Surgeon. JAMA Surgery, 2017, 152, 410.	2.2	32
78	Frontiers in robot-assisted retroperitoneal oncological surgery. Nature Reviews Urology, 2017, 14, 731-741.	1.9	19
79	Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device. Urology, 2017, 109, 216-221.	0.5	13
80	Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 606.e1-606.e7.	0.8	26
81	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2117-2136.	3.3	234
82	Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?. EJNMMI Research, 2017, 7, 34.	1.1	10
83	International Consultation on Urological Diseases and European Association of Urology International Consultation on Minimally Invasive Surgery in Urology: laparoscopic and robotic adrenalectomy. BJU International, 2017, 119, 13-21.	1.3	49
84	Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes. Urology, 2017, 100, 151-157.	0.5	49
85	Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nature Reviews Urology, 2017, 14, 90-97.	1.9	78
86	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget, 2017, 8, 104182-104192.	0.8	20
87	Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Research, 2017, 7, 80.	1.1	33
88	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine, 2017, 31, 696-702.	1.2	34
89	Reproducibility of Cold Uptake Radiomics in 99m Tc-Sestamibi SPECT Imaging of Renal Cell Carcinoma. , 2017, , .		0
90	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 5077-5077.	0.8	12

#	ARTICLE	IF	CITATIONS
91	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	0.8	7
92	Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses.. Journal of Clinical Oncology, 2017, 35, 430-430.	0.8	7
93	Incidence of T3a upstaging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis.. Journal of Clinical Oncology, 2017, 35, 4588-4588.	0.8	0
94	Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. BJU International, 2016, 118, 112-117.	1.3	24
95	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. Clinical Genitourinary Cancer, 2016, 14, e515-e520.	0.9	19
96	Reply to Valerian Ciprian Lucan, Salvatore ButticiÃ², Rosa Pappalardo, Carlo Magno's Letter to the Editor re: Mark W. Ball, Nathaniel Readal, Phillip M. Pierorazio, Mohamad E. Allaf. Splitting One Kidney into Two: Robotic Partial Kidney Transplant in a Porcine Model. Eur Urol 2016;69:968-969. European Urology, 2016, 70, e82.	0.9	0
97	A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention. Journal of Urology, 2016, 196, 1356-1362.	0.2	51
98	Variability of interobserver agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (<scp>RCC</scp>): independent analysis from a phase <scp>II</scp> trial. BJU International, 2016, 117, 629-635.	1.3	18
99	Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. Current Urology Reports, 2016, 17, 4.	1.0	7
100	Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes. Current Urology Reports, 2016, 17, 41.	1.0	10
101	Splitting One Kidney into Two: Robotic Partial Kidney Transplant in a Porcine Model. European Urology, 2016, 69, 968-969.	0.9	4
102	Prospective Evaluation of 99mTc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology, 2016, 69, 413-416.	0.9	121
103	Clinical, pathologic, and genomic profiles of exceptional responders to anti-PD1 therapy in renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 625-625.	0.8	9
104	[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget, 2016, 7, 56471-56479.	0.8	49
105	Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 299-299.	0.8	0
106	Recent advances in immunotherapy for kidney cancer. Discovery Medicine, 2016, 21, 305-13.	0.5	13
107	Angiomyolipoma with epithelial cysts: Add one to the differential of cystic renal lesions. International Journal of Urology, 2015, 22, 1081-1082.	0.5	5
108	A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. BJU International, 2015, 116, 920-923.	1.3	50

#	ARTICLE	IF	CITATIONS
109	Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2015, 2015, 1-6.	0.6	7
110	Management of Metachronous Bilateral Testis Cancer in a Patient with Pre-B Cell ALL. <i>Case Reports in Urology</i> , 2015, 2015, 1-4.	0.1	1
111	Nuclear imaging of renal tumours: a step towards improved risk stratification. <i>Nature Reviews Urology</i> , 2015, 12, 445-450.	1.9	13
112	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. <i>Urology</i> , 2015, 86, 942-946.	0.5	10
113	Partial Nephrectomy for the Treatment of Translocation Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e199-e201.	0.9	13
114	Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: A multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e9-112.e14.	0.8	36
115	The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 166.e17-166.e20.	0.8	11
116	Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. <i>Journal of Urology</i> , 2015, 194, 903-909.	0.2	32
117	Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2015, 29, 877-882.	1.2	152
118	Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy. <i>Journal of Urology</i> , 2015, 193, 36-40.	0.2	105
119	Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. <i>Oncotarget</i> , 2015, 6, 33733-33742.	0.8	44
120	Outcomes of partial nephrectomy in patients who meet percutaneous ablation criteria. <i>Central European Journal of Urology</i> , 2015, 68, 132-6.	0.2	6
121	Robotic adrenalectomy: the jury is still out. <i>Gland Surgery</i> , 2015, 4, 277-8.	0.5	3
122	Robot-Assisted Adrenalectomy (Total, Partial, & Metastasectomy). <i>Urologic Clinics of North America</i> , 2014, 41, 539-547.	0.8	8
123	Pathological characteristics and radiographic correlates of complex renal cysts. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1010-1016.	0.8	35
124	Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. <i>Human Pathology</i> , 2014, 45, 244-248.	1.1	22
125	ANATOMICAL EXTENT OF LYMPH NODE DISSECTION: IMPACT ON MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2004, 172, 1840-1844.	0.2	313
126	Active Surveillance Versus Immediate Intervention for Small Renal Masses: A Cost-Effectiveness and Clinical Decision Analysis. <i>Journal of Urology</i> , 0, , .	0.2	6